A phase II study of erlotinib in benefitted patients with asymptomatic brain metastases advanced non-small cell lung cancer by chemotherapy

Trial Profile

A phase II study of erlotinib in benefitted patients with asymptomatic brain metastases advanced non-small cell lung cancer by chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2008

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 19 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top